Abstract
Obesity is a complex pathology that affects virtually all stages of life, regardless of socioeconomic groups. GLP-1 analogues are potentially promising drugs for weight loss in obese or overweight adults and at least one comorbidity. An integrative review of the use of the GLP-1 analogue semaglutide in the treatment of obesity and weight loss therapy was reviewed, analyzing the STEP (Semaglutide Treatment Effect in People with Obesity) study.
Cite
CITATION STYLE
Galiassi, G. E. R., Cruz, P. O. N. P. T., Figueiredo, C. Y. de B., Bezerra, T. R. G., Martins, A. C., & Silva, L. M. da. (2022). THE USE OF SEMAGLUTIDE (ANALOG OF GLP-1) IN THE TREATMENT OF OBESITY. International Journal of Health Science, 2(43), 2–6. https://doi.org/10.22533/at.ed.1592432201088
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
